Selective targeting of GARP-LTGFβ axis in the tumor microenvironment augments PD-1 blockade via enhancing CD8 + T cell antitumor immunity.
Anqi LiYuzhou ChangNo-Joon SongXingjun WuDongjun ChungBrian P RiesenbergMaria VelegrakiGiuseppe D GiulianiKomal DasTamio OkimotoHyunwoo KwonKarthik B ChakravarthyChelsea BolyardYi WangKai HeMargaret E Gatti-MaysJayajit DasYiping YangDaniel T GewirthQin MaDavid CarboneZihai LiPublished in: Journal for immunotherapy of cancer (2022)
T cell trafficking and functionality in the tumor, and overcome primary resistance to anti-PD-1 ICB. PIIO-1 therefore warrants clinical development as a novel cancer immunotherapeutic.